Image credit: Rayence booth RSNA 2017, Rayence US
On 10th May, Rayence Corporation published its provisional financial results for Q1 2021. These results show that quarterly sales returned to growth following four consecutive quarters of sales decline. Group quarterly sales reached ₩31.5 bn, compared with ₩27.2 bn during Q1 2020, an increase of approximately +16% year-on-year.
| Subsidiary | Incorporation | Control |
|---|---|---|
| Rayence Inc | USA | 100% |
| OSKO Inc | USA | 80.65% |
| OSKO MEX | Mexico | 100% |
| Woorien | Korea | 92.31% |
| Rayence & MyVet | USA | 92.31% |
| Qpix | USA | 100% |
| A-Pharm | Korea | 63.02% |
| P&V | Korea | 41.75% |
| Rayence China | China | 100% |
Subscribe
Processing…
Success! You're on the list.
Whoops! There was an error and we couldn't process your subscription. Please reload the page and try again.
Prerequisite Market Intelligence 